Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Treatment Choice, Satisfaction and Quality of Life in Patients With Graves’ Disease
source: Clinical Endocrinology
year: 2018
authors: Conaglen HM, Tamatea JAU, Conaglen JV, Elston MS
summary/abstract:Background:
Thyrotoxicosis, most often caused by Graves’ disease (GD), when treated inadequately may result in premature mortality. There is little consensus as to which of the 3 treatment options available – antithyroid drugs (ATD), radioactive iodine (RAI) and surgery, is better.
Aims:
(i) To assess factors involved in treatment choice and treatment satisfaction in patients treated for Graves’ disease; (ii) To assess quality of life (QoL) following treatment of Graves’ disease.
Method:
Participants were selected from a prospective study cohort assessing thyrotoxicosis incidence and severity. Of the 172 eligible patients with Graves’ disease, 123 treated patients participated (64% had received ATD only, 11% RAI and 25% total thyroidectomy, the latter 2 usually after a period of ATD), along with 18 untreated patients with newly diagnosed Graves’ disease (overall participation rate, 73%). Consented patients completed a questionnaire detailing factors involved in treatment choice, QoL and satisfaction with treatment.
Results:
Participants reported that the most important factors in choosing a treatment were the following: the effects on activities of daily living, concern about use of radioiodine, possibility of depression or anxiety, and doctor’s recommendations. Satisfaction levels were high across all 3 treatment types. QoL 1-year following treatment was higher than in untreated patients, and comparable with other international studies.
Conclusions:
Patient satisfaction with therapy and QoL does not differ by treatment type. Therefore, clinical and social factors, in combination with patient choice and resource availability, should determine which treatment modality patients with Graves’ disease should receive.
DOI: 10.1111/cen.13611
read more full text
Related Content
-
Decision Aid for Patients with Graves’ DiseaseThere are three effective treatments for...
-
A Mild Risk of Neonatal Hyperthyroidism Follows Radioactive Iodine Therapy for Graves’ Disease Prior to PregnancyGraves’ disease is an autoimmune condi...
-
Radioactive Iodine Therapy vs. Antithyroid Medications for Graves’ DiseaseGraves disease is the most common cause ...
-
Graves’ Disease Awareness Webinar – December 18, 2023 (Co-Hosted by GDATF and AAES)https://www.youtube.com/watch?v=HDPiQN8d...
-
A 6-Year Follow-Up of a Randomized Prospective Trial Comparing Methimazole Treatment With or Without Exogenous L-Thy...Objective: Antithyroid drug therapy is ...
-
Barbra Sue Miller, MDBarbra S. Miller is the Co-Director of T...
-
Management of Endocrine Disease: Rituximab Therapy for Graves’ Orbitopathy – Lessons From Randomized Con...Rituximab (RTX) use in open-label series...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.